Skip to main content
SpringerLink
Log in

Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010–2016 in Fujian, China

  • Original Article
  • Published:
Archives of Osteoporosis Aims and scope Submit manuscript

Abstract

Summary

This study demonstrates a low anti-osteoporosis drug treatment rate (22.1% in women, 9.5% in men) after osteoporotic fracture in the real-world setting of Fujian, China. The primary medication was calcitonin. The suboptimal treatment was particularly critical among men, low-level hospitals, wrist/vertebral fracture, and the younger elderly patients.

Introduction

The objective of this study was to investigate the prescription patterns and related influencing factors of anti-osteoporosis drug prescribing after osteoporotic fracture in Fujian, China, between 2010 and 2016.

Methods

This is a retrospective cohort study based on an existing electronic health record database (National Healthcare Big Data in Fuzhou, China, 37 hospitals included). Patients over 50 years old with newly diagnosed osteoporotic fractures between 2010 and 2016 were included. Postfracture osteoporosis therapies were summarized by overall and fracture site. Multivariate logistic regression was performed to identify influencing factors of anti-osteoporosis medication (AOM) prescription.

Results

Overall, 22.1% of women and 9.5% of men over 50 years old received AOM treatment after osteoporotic fracture within 1 year during 2010–2016, with particular low use of bisphosphonates, 5.3% in women and 1.5% in men. The highest rate of AOM treatment was found in patients with hip fracture (24.5%), followed by vertebral fracture (14.2%) and wrist fracture (2.3%). Of the AOM-treated patients, 90.5% received calcitonin therapy. The treatment rate of AOM showed a slight decline during 2010–2016, but steady rise trends were observed in Ca/vitamin D (VD) prescription. Hospital level, age, sex, previous osteoporosis, previous AOM prescription, and previous oral glucocorticoid prescription were strong predicting factors of AOM prescription.

Conclusion

In a real-world setting, AOM treatment was suboptimal and the treatment rate even decreased over time among osteoporosis fracture patients in Fujian, China. The suboptimal treatment was particularly critical among men, low-level hospitals, wrist/vertebral fracture, and the younger elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Alejandro P, Constantinescu F (2018) A review of osteoporosis in the older adult: an update. Rheum Dis Clin N Am 44(3):437–451. https://doi.org/10.1016/j.rdc.2018.03.004

    Article  Google Scholar 

  2. Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https://doi.org/10.1007/s11657-013-0136-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Strom O, Borgstrom F, Kanis JA, Compston J, Cooper C, McCloskey EV et al (2011) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59–155. https://doi.org/10.1007/s11657-011-0060-1

    Article  CAS  PubMed  Google Scholar 

  4. Zeng Q, Li N, Wang Q, Feng J, Sun D, Zhang Q et al (2019) The prevalence of osteoporosis in China, a nationwide, multicenter DXA survey. J Bone Miner Res 34(10):1789–1797. https://doi.org/10.1002/jbmr.3757

    Article  PubMed  Google Scholar 

  5. Wang Y, Tao Y, Hyman ME, Li J, Chen Y (2009) Osteoporosis in China. Osteoporos Int 20(10):1651–1662. https://doi.org/10.1007/s00198-009-0925-y

    Article  CAS  PubMed  Google Scholar 

  6. Si L, Winzenberg TM, Jiang Q, Chen M, Palmer AJ (2015) Projection of osteoporosis-related fractures and costs in China: 2010-2050. Osteoporos Int 26(7):1929–1937. https://doi.org/10.1007/s00198-015-3093-2

    Article  CAS  PubMed  Google Scholar 

  7. Melton LR, Crowson CS, O'Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9(1):29–37

    Article  PubMed  Google Scholar 

  8. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA. 302(14):1573–1579. https://doi.org/10.1001/jama.2009.1462

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Jean S, O'Donnell S, Lagace C, Walsh P, Bancej C, Brown JP et al (2013) Trends in hip fracture rates in Canada: an age-period-cohort analysis. J Bone Miner Res 28(6):1283–1289. https://doi.org/10.1002/jbmr.1863

    Article  PubMed  Google Scholar 

  10. Chen IJ, Chiang CY, Li YH, Chang CH, Hu CC, Chen DW et al (2015) Nationwide cohort study of hip fractures: time trends in the incidence rates and projections up to 2035. Osteoporos Int 26(2):681–688. https://doi.org/10.1007/s00198-014-2930-z

    Article  PubMed  Google Scholar 

  11. Nymark T, Lauritsen JM, Ovesen O, Rock ND, Jeune B (2006) Decreasing incidence of hip fracture in the Funen County. Denmark Acta Orthop 77(1):109–113. https://doi.org/10.1080/17453670610045777

    Article  PubMed  Google Scholar 

  12. Dimai HP, Svedbom A, Fahrleitner-Pammer A, Pieber T, Resch H, Zwettler E et al (2011) Epidemiology of hip fractures in Austria: evidence for a change in the secular trend. Osteoporos Int 22(2):685–692. https://doi.org/10.1007/s00198-010-1271-9

    Article  CAS  PubMed  Google Scholar 

  13. Hawley S, Leal J, Delmestri A, Prieto-Alhambra D, Arden NK, Cooper C et al (2016) Anti-osteoporosis medication prescriptions and incidence of subsequent fracture among primary hip fracture patients in England and Wales: an interrupted time-series analysis. J Bone Miner Res 31(11):2008–2015. https://doi.org/10.1002/jbmr.2882

    Article  CAS  PubMed  Google Scholar 

  14. Kim SC, Kim MS, Sanfelix-Gimeno G, Song HJ, Liu J, Hurtado I et al (2015) Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med 128(5):519–526. https://doi.org/10.1016/j.amjmed.2015.01.014

    Article  PubMed  PubMed Central  Google Scholar 

  15. Munson JC, Bynum JP, Bell JE, Cantu R, McDonough C, Wang Q et al (2016) Patterns of prescription drug use before and after fragility fracture. JAMA Intern Med 176(10):1531–1538. https://doi.org/10.1001/jamainternmed.2016.4814

    Article  PubMed  PubMed Central  Google Scholar 

  16. Shah A, Prieto-Alhambra D, Hawley S, Delmestri A, Lippett J, Cooper C et al (2017) Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study. Osteoporos Int 28(1):169–178. https://doi.org/10.1007/s00198-016-3811-4

    Article  CAS  PubMed  Google Scholar 

  17. Gonnelli S, Caffarelli C, Iolascon G, Bertoldo F, Letizia MG, Patti A et al (2017) Prescription of anti-osteoporosis medications after hospitalization for hip fracture: a multicentre Italian survey. Aging Clin Exp Res 29(5):1031–1037. https://doi.org/10.1007/s40520-016-0681-8

    Article  PubMed  Google Scholar 

  18. Yu YM, Lee JY, Lee E (2017) Access to anti-osteoporosis medication after hip fracture in Korean elderly patients. Maturitas. 103:54–59. https://doi.org/10.1016/j.maturitas.2017.06.021

    Article  PubMed  Google Scholar 

  19. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA (2004) New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 57(12):1288–1294. https://doi.org/10.1016/j.jclinepi.2004.03.012

    Article  PubMed  Google Scholar 

  20. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8

    Article  CAS  PubMed  Google Scholar 

  21. Belhassen M, Confavreux CB, Cortet B, Lamezec L, Ginoux M, Van Ganse E (2017) Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up. Osteoporos Int 28(3):853–862. https://doi.org/10.1007/s00198-016-3789-y

    Article  CAS  PubMed  Google Scholar 

  22. van der Velde RY, Wyers CE, Teesselink E, Geusens P, van den Bergh J, de Vries F et al (2017) Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity. Bone. 94:50–55. https://doi.org/10.1016/j.bone.2016.10.013

    Article  PubMed  Google Scholar 

  23. Li JT (2013) Analysis on the trend and application of anti-osteoporosis drugs in our hospital. Hebei Med 17:2683–2684. https://doi.org/10.3969/j.issn.1002-7386.2013.17.071

    Article  Google Scholar 

  24. Zhang XC, Wan B, Zhou WM, Pan LY. Investigation on the use of anti-osteoporosis drugs in outpatient department of a hospital. People’s military doctors 2019;62(2):142-7

  25. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57. https://doi.org/10.1007/s00198-012-2074-y

    Article  CAS  PubMed  Google Scholar 

  26. Forciea MA, McLean RM, Qaseem A (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women. Ann Intern Med 167(12):904. https://doi.org/10.7326/L17-0490

    Article  PubMed  Google Scholar 

  27. Ma YZ, Wang YP, Liu Q, Li CL, Ma X, Wang YJ et al (2019) Guidelines for diagnosis and treatment of osteoporosis in the elderly in China (2018). Chin J Gerontol 39(11):2561–2579. https://doi.org/10.3969/j.issn.1005-9202.2019.11.001

    Article  Google Scholar 

  28. Wang PW, Li YZ, Zhuang HF, Yu HM, Cai SQ, Xu H et al (2019) Anti-osteoporosis medications associated with decreased mortality after hip fracture. Orthop Surg 11(5):777–783. https://doi.org/10.1111/os.12517

    Article  PubMed  PubMed Central  Google Scholar 

  29. Klop C, Gibson-Smith D, Elders PJ, Welsing PM, Leufkens HG, Harvey NC et al (2015) Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010. Osteoporos Int 26(7):1919–1928. https://doi.org/10.1007/s00198-015-3098-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Fraser LA, Ioannidis G, Adachi JD, Pickard L, Kaiser SM, Prior J et al (2011) Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 22(3):789–796. https://doi.org/10.1007/s00198-010-1359-2

    Article  PubMed  Google Scholar 

  31. Cadarette SM, Katz JN, Brookhart MA, Levin R, Stedman MR, Choudhry NK, Solomon DH (2008) Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004. J Rheumatol 35(2):319–326

    PubMed  Google Scholar 

  32. Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20(2):299–307. https://doi.org/10.1007/s00198-008-0651-x

    Article  CAS  PubMed  Google Scholar 

  33. Alves SM, Economou T, Oliveira C, Ribeiro AI, Neves N, Gomez-Barrena E et al (2013) Osteoporotic hip fractures: bisphosphonates sales and observed turning point in trend. A population-based retrospective study. Bone. 53(2):430–436. https://doi.org/10.1016/j.bone.2012.12.014

    Article  PubMed  Google Scholar 

  34. Zhang J, Delzell E, Curtis JR, Hooven F, Gehlbach SH, Anderson FJ et al (2014) Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone mass. Osteoporos Int 25(1):317–324. https://doi.org/10.1007/s00198-013-2444-0

    Article  CAS  PubMed  Google Scholar 

  35. Corsonello A, Pedone C, Incalzi RA (2010) Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 17(6):571–584. https://doi.org/10.2174/092986710790416326

    Article  CAS  PubMed  Google Scholar 

  36. Tsoi CS, Chow JY, Choi KS, Li HW, Nie JX, Tracy CS et al (2014) Medical characteristics of the oldest old: retrospective chart review of patients aged 85+ in an academic primary care centre. BMC Res Notes 7:340. https://doi.org/10.1186/1756-0500-7-340

    Article  PubMed  PubMed Central  Google Scholar 

  37. Bor A, Matuz M, Gyimesi N, Biczok Z, Soos G, Doro P (2015) Gender inequalities in the treatment of osteoporosis. Maturitas. 80(2):162–169. https://doi.org/10.1016/j.maturitas.2014.11.001

    Article  PubMed  Google Scholar 

  38. Yusuf AA, Matlon TJ, Grauer A, Barron R, Chandler D, Peng Y (2016) Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries. Arch Osteoporos 11(1):31. https://doi.org/10.1007/s11657-016-0285-0

    Article  PubMed  Google Scholar 

  39. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56(1):208–214. https://doi.org/10.1002/art.22294

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank China Electronics Corporation (CEC) Data for granting access to the National Health database.

Author information

Authors and Affiliations

  1. NHC Key Lab. of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research), Public Health School, Fudan University, Shanghai, 200032, China

    Xing Wang

  2. Shanghai Synyi Medical Technology Co., Ltd, 5th Floor, 232 Liangjing Road, Shanghai, China

    Xing Wang, Chunming Li, Yan He, Tao Wang, Heng Zhang, Zihui Ma, Handong Ma & Hongxin Zhao

  3. Department of Computer Science, Shanghai Jiao Tong University, Shanghai, 200240, China

    Handong Ma

Authors
  1. Xing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chunming Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Heng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zihui Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Handong Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hongxin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Handong Ma or Hongxin Zhao.

Ethics declarations

This study was approved by China Ethnic Committee of Registering Clinical Trials (ChiECRCT-20190178).

Conflicts of interest

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, X., Li, C., He, Y. et al. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010–2016 in Fujian, China. Arch Osteoporos 15, 134 (2020). https://doi.org/10.1007/s11657-020-00798-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11657-020-00798-1

Keywords

Search

Navigation